These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 7892157)

  • 1. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
    Champème MH; Bièche I; Hacène K; Lidereau R
    Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
    Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
    Berns EM; Klijn JG; van Putten WL; van Staveren IL; Portengen H; Foekens JA
    Cancer Res; 1992 Mar; 52(5):1107-13. PubMed ID: 1737370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
    Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
    Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors for recurrent breast cancer: univariate and multivariate analyses including histologic grade and amplification of the c-erbB-2 proto-oncogene.
    Tsuda H; Tsugane S; Fukutomi T; Nanasawa T; Yamamoto H; Hirohashi S
    Jpn J Clin Oncol; 1992 Aug; 22(4):244-9. PubMed ID: 1359174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the int-1, int-2, c-myc, and neu oncogenes in human breast carcinomas.
    Meyers SL; O'Brien MT; Smith T; Dudley JP
    Cancer Res; 1990 Sep; 50(18):5911-8. PubMed ID: 1975511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
    Gaffey MJ; Frierson HF; Williams ME
    Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.
    Tsuda H; Hirohashi S; Shimosato Y; Hirota T; Tsugane S; Yamamoto H; Miyajima N; Toyoshima K; Yamamoto T; Yokota J
    Cancer Res; 1989 Jun; 49(11):3104-8. PubMed ID: 2566377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer.
    Hui R; Campbell DH; Lee CS; McCaul K; Horsfall DJ; Musgrove EA; Daly RJ; Seshadri R; Sutherland RL
    Oncogene; 1997 Sep; 15(13):1617-23. PubMed ID: 9380415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis.
    Scorilas A; Trangas T; Yotis J; Pateras C; Talieri M
    Br J Cancer; 1999 Dec; 81(8):1385-91. PubMed ID: 10604737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ERBB2 amplification in breast cancer with a high rate of proliferation.
    Borg A; Baldetorp B; Fernö M; Killander D; Olsson H; Sigurdsson H
    Oncogene; 1991 Jan; 6(1):137-43. PubMed ID: 1671531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Amplification of c-myc and c-erbbeta-2(HER-2/neu) in breast cancer without axillary lymph node metastasis: correlation with other prognostic parameters].
    Lizard-Nacol S; Arnould L; Riedinger JM; Arnal M; Collin F; Guerrin J
    Bull Cancer; 1994 Sep; 81(9):780-4. PubMed ID: 7703567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
    Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
    Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors.
    Morrison BW; Leder P
    Oncogene; 1994 Dec; 9(12):3417-26. PubMed ID: 7970700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proto-oncogene amplification and human breast tumor phenotype.
    Adnane J; Gaudray P; Simon MP; Simony-Lafontaine J; Jeanteur P; Theillet C
    Oncogene; 1989 Nov; 4(11):1389-95. PubMed ID: 2554239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
    Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G
    Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.
    Tiwari RK; Borgen PI; Wong GY; Cordon-Cardo C; Osborne MP
    Anticancer Res; 1992; 12(2):419-25. PubMed ID: 1349794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogene amplification per se: an independent prognostic factor in human breast cancer.
    Champème MH; Bièche I; Hacène K; Lidereau R
    Mol Carcinog; 1994 Dec; 11(4):189-91. PubMed ID: 7999260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer.
    Le Roy X; Escot C; Brouillet JP; Theillet C; Maudelonde T; Simony-Lafontaine J; Pujol H; Rochefort H
    Oncogene; 1991 Mar; 6(3):431-7. PubMed ID: 1707153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.